Sequenom, New England Biolabs Ink Deal for Epigenetics Technology | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – New England Biolabs and Sequenom said after the close of the market on Tuesday they have signed a licensing and co-marketing agreement for the commercialization of tools for epigenetics research.

They also announced the launch of the first product stemming from the research collaboration, which served as the basis for the agreement, the EpiMark Methylated DNA Enrichment Kit from NEB.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.